Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

[1]  A. Phillips,et al.  The role of HIV in serious diseases other than AIDS , 2008, AIDS.

[2]  S. Hammer,et al.  Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. , 2008, JAMA.

[3]  Peter Reiss,et al.  Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. , 2008, JAMA.

[4]  J. Gatell,et al.  Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. , 2008, The Journal of infectious diseases.

[5]  F. Raffi,et al.  European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV‐infected adults , 2008, HIV medicine.

[6]  Gemma Navarro,et al.  Determinants of HIV Progression and Assessment of the Optimal Time to Initiate Highly Active Antiretroviral Therapy: PISCIS Cohort (Spain) , 2008, Journal of acquired immune deficiency syndromes.

[7]  Anne M Johnson,et al.  Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients , 2007, Journal of acquired immune deficiency syndromes.

[8]  Haitao Chu,et al.  Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution , 2007, Statistics in medicine.

[9]  C. Fraser,et al.  CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater , 2007, Journal of acquired immune deficiency syndromes.

[10]  J. Sterne,et al.  Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies , 2007, AIDS.

[11]  O. Kirk,et al.  Class of antiretroviral drugs and the risk of myocardial infarction. , 2007, The New England journal of medicine.

[12]  B. Gazzard,et al.  When should antiretroviral therapy for HIV be started? , 2007, BMJ : British Medical Journal.

[13]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[14]  Melissa Skanderson,et al.  Development and Verification of a “Virtual” Cohort Using the National VA Health Information System , 2006, Medical care.

[15]  Jerome H. Carter,et al.  Distribution of health care expenditures for HIV-infected patients. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  J. Gatell,et al.  Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. , 2006, Archives of internal medicine.

[17]  J. Sterne,et al.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.

[18]  S. Mallal,et al.  Antiretroviral-therapy-associated lipoatrophy: current status and future directions. , 2005, Sexual health.

[19]  J. Sterne,et al.  Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. , 2005, Journal of clinical epidemiology.

[20]  Jonathan AC Sterne,et al.  Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study , 2005, The Lancet.

[21]  P. Harrigan,et al.  When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. , 2005, The Lancet. Infectious diseases.

[22]  Richard D Moore,et al.  An Improvement in Virologic Response to Highly Active Antiretroviral Therapy in Clinical Practice From 1996 Through 2002 , 2005, Journal of acquired immune deficiency syndromes.

[23]  G. Behrens.  Cardiovascular risk and body-fat abnormalities in HIV-infected adults. , 2005, The New England journal of medicine.

[24]  Gemma Navarro,et al.  Características clinicoepidemiológicas y tendencias en el tratamiento antirretroviral de una cohorte de pacientes con infección por el virus de la inmunodeficiencia humana. Cohorte PISCIS , 2005 .

[25]  B. Gazzard,et al.  Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice , 2005, AIDS.

[26]  Diane V Havlir,et al.  The case for earlier treatment of HIV infection. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  S. Cole,et al.  Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies , 2004, Statistics in medicine.

[28]  M. Schechter.  Therapy for early HIV infection: how far back should the pendulum swing? , 2004, The Journal of infectious diseases.

[29]  J. Sterne,et al.  Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy , 2004, Statistics in medicine.

[30]  O. Kirk,et al.  Combination antiretroviral therapy and the risk of myocardial infarction. , 2003, The New England journal of medicine.

[31]  Kholoud Porter,et al.  Determinants of survival following HIV-1 seroconversion after the introduction of HAART , 2003, The Lancet.

[32]  J. Robins,et al.  Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. , 2003, American journal of epidemiology.

[33]  B. Yip,et al.  Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[34]  H. Lane,et al.  When To Start Therapy for HIV Infection: A Swinging Pendulum in Search of Data , 2003, Annals of Internal Medicine.

[35]  Maria Deloria-Knoll,et al.  Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata , 2003, Annals of Internal Medicine.

[36]  Timothy R Sterling,et al.  Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  A. Mocroft,et al.  Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study , 2002, AIDS.

[38]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[39]  G. Beall,et al.  Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. , 2002, The New England journal of medicine.

[40]  Julio S. G. Montaner,et al.  Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. , 2001, JAMA.

[41]  R. Pomerantz.  Initiating antiretroviral therapy during HIV infection: confusion and clarity. , 2001, JAMA.

[42]  R Weber,et al.  HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. , 2001, JAMA.

[43]  H. Jacqmin-Gadda,et al.  Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: the Aquitaine Cohort, 1996-1997. , 2001, American journal of epidemiology.

[44]  N. Hansen,et al.  Zidovudine and Stavudine Sequencing in HIV Treatment Planning: Findings From the CHORUS HIV Cohort , 2001, Journal of acquired immune deficiency syndromes.

[45]  M. Moroni,et al.  Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.

[46]  D. Costagliola,et al.  Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor , 2000, AIDS.

[47]  T. Chun,et al.  Latent reservoirs of HIV: obstacles to the eradication of virus. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[48]  C. Sabin,et al.  The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. , 1999, AIDS.

[49]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[50]  R. Hogg,et al.  Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[51]  A. Mocroft,et al.  Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor , 1998, AIDS.

[52]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[53]  R. Reves,et al.  The case for conservative management of early HIV disease. , 1998, JAMA.

[54]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[55]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[56]  Maria Prins,et al.  Pre‐AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users , 1997, AIDS.

[57]  J. Rockstroh,et al.  Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV‐infected patients , 1997, AIDS.

[58]  H. Brodt,et al.  Changing incidence of AIDS‐defining illnesses in the era of antiretroviral combination therapy , 1997, AIDS.

[59]  Manuel Battegay,et al.  Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study , 1997, BMJ.

[60]  J. Nielsen,et al.  Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[61]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[62]  J. Darbyshire,et al.  Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.

[63]  D. Ho,et al.  Time to hit HIV, early and hard. , 1995, The New England journal of medicine.

[64]  Ann Marie Swart,et al.  Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection , 1994, The Lancet.

[65]  H. Masur.  Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. , 1993, The New England journal of medicine.

[66]  J. Goudsmit,et al.  Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. , 1988, The Journal of infectious diseases.

[67]  J. Phair,et al.  The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. , 1987, American journal of epidemiology.

[68]  S. Hammer,et al.  Antiretroviral Treatment of Adult HIV Infection 2008 Recommendations of the International AIDS Society–USA Panel , 2008 .

[69]  Peter J. Hurley,et al.  Development and Verification of TAPM , 2008 .

[70]  When should antiretroviral therapy for HIV be started? , 2007, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[71]  Michael S Saag,et al.  Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .

[72]  The Swiss Hiv Cohort Study,et al.  The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristics , 2005, Sozial- und Präventivmedizin.

[73]  D. Podzamczer,et al.  [Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]. , 2005, Medicina clinica.

[74]  Martin S. Hirsch,et al.  Treatment for adult HIV infection. , 2004 .

[75]  Rodolphe Thiébaut,et al.  Combination antiretroviral therapy and the risk of myocardial infarction , 2003 .

[76]  N. Hansen,et al.  Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort. , 2001 .

[77]  Eyton,et al.  A CONTROLLED TRIAL OF TWO NUCLEOSIDE ANALOGUES PLUS INDINAVIR IN PERSONS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION AND CD4 CELL COUNTS OF 200 PER CUBIC MILLIMETER OR LESS , 2000 .

[78]  R. Brettle,et al.  mortality from natural causes associated with HIV disease progression : evidence from the European seroconverter study among injecting drug users , 1997 .

[79]  From the Centers for Disease Control. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with HIV. , 1992, JAMA.